Drug Trial Radar · NCT05156450
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Dec 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jan 1, 2022
Primary completion
Oct 1, 2023
Study completion Jan 1, 2024
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II clinical study of TQB3616 capsules in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer, to determine the dose for further clinical studies and to evaluate the safety and efficacy of this combined therapy.
Conditions
- Prostatic Neoplasms, Castration-Resistant
- Drug Therapy, Combination
Interventions
TQB3616 Capsules Combined With Abiraterone Acetate Plus PrednisoneDrug
Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-month radiographic progression-free survival (rPFS) rateTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.